Search results for " jaw"

showing 10 items of 171 documents

Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw

2016

To date there is no consensus on the role of diabetes in the development of medication-related osteonecrosis of the jaws (MR-ONJ). Therefore, this study aimed to investigate the prevalence of diabetes and pathological glucose metabolism in patients with MR-ONJ compared to the general population. All maxillofacial surgery inpatients in one year at our department were investigated regarding diagnosis, anamnesis, medication, and blood glucose readings. 1374 records were analyzed. 35 patients with MR-ONJ were identified. Diabetics accounted for 14.3%. No significant difference in the prevalence of known diabetes was found, except for pathological glucose metabolism in patients with MR-ONJ (p &l…

medicine.medical_specialtyPopulationArticle03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicinediabetes; hyperglycemia; bisphosphonates; denosumab; MR-ONJ; BP-ONJRisk factoreducationGeneral DentistryPathologicalbisphosphonatesAnamnesiseducation.field_of_studyBP-ONJdiabetesbusiness.industrySignificant differencedenosumab030206 dentistrymedicine.diseaseSurgerylcsh:RK1-715Denosumab030220 oncology & carcinogenesislcsh:DentistryMR-ONJhyperglycemiaOsteonecrosis of the jawbusinessmedicine.drugDentistry Journal; Volume 4; Issue 2; Pages: 17
researchProduct

Reply to Athanassios Kyrgidis, Zisis Teleioudis and Konstantinos Vahtsevanos’ Letter to the Editor re: Christian Walter, Bilal Al-Nawas, Knut A. Gröt…

2009

medicine.medical_specialtyProstate cancerBisphosphonate-associated osteonecrosis of the jawLetter to the editorbusiness.industryUrologyGeneral surgerymedicineAdvanced diseasebusinessmedicine.diseaseSurgeryEuropean Urology
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ -

2014

Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a relatively rare but serious side effect of bisphosphonate (BP)-based treatments. This retrospective study aimed to investigate the risk factors and predictive markers in cases where patients were refractory to a recommended conservative treatment offered in our hospital. Patients and Methods: This single-center study collated the medical records of all patients treated for BRONJ between 2004 and 2011. A complete medical history, including detailed questionnaires, was collected for all patients, focusing on identifying underlying risk factors, clinical features, location and bone marker levels of BRONJ. Results: The mea…

medicine.medical_specialtySide effectbusiness.industryMedical recordmedicine.medical_treatmentResearchRetrospective cohort studyOdontologíaBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryN-terminal telopeptideInternal medicineUNESCO::CIENCIAS MÉDICASMedicineMedical historyOral SurgerybusinessOsteonecrosis of the jawGeneral DentistryProgressive disease
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence-a multi-centre study

2011

Abstract Introduction Bisphosphonates (BPs) are powerful drugs that inhibit bone metabolism. Adverse side effects are rare but potentially severe such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, research has primarily focused on the development and progression of BRONJ in cancer patients with bone metastasis, who have received high dosages of BPs intravenously. However, a potential dilemma may arise from a far larger cohort, namely the millions of osteoporosis patients on long-term oral BP therapy. Patients and methods This current study assessed 470 cases of BRONJ diagnosed between 2004 and 2008 at eleven different European clinical centres and has resulted in the …

medicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.medical_treatmentOral Surgical ProceduresOsteoporosisAdministration OralSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansMedical historyAdverse effectBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryContraindicationsOsteonecrosisBisphosphonatemedicine.diseaseSurgeryZoledronic acidOtorhinolaryngologyCohortOral and maxillofacial surgeryOsteoporosisSurgeryOral Surgeryosteoporosis bisphosphonates ostenecrosis jawsOsteonecrosis of the jawbusinessJaw Diseasesmedicine.drug
researchProduct

Weight loss in Alzheimer’s disease, vascular dementia and dementia with Lewy bodies: Impact on mortality and hospitalization by dementia subtype

2021

Objectives Loss of weight is associated with cognitive decline as well as several adverse outcomes in dementia. The aim of this study was to assess whether weight loss is associated with mortality and hospitalization in dementia subtypes. Methods A cohort of 11,607 patients with dementia in Alzheimer's disease (AD), vascular dementia (VD), or dementia with Lewy bodies (DLB) was assembled from a large dementia care health records database in Southeast London. A natural language processing algorithm was developed to established whether loss of weight was recorded around the time of dementia diagnosis. Cox proportional hazard models were applied to examine the associations of reported weight l…

medicine.medical_specialtyWeight lossInternal medicinemental disordersmedicineDementiaCognitive declineVascular dementiaImpact on mortality and hospitalization by dementia subtype.- International journal of geriatric psychiatry 2021 [Soysal P. Tan S. G. Rogowska M. Jawad S. Smith L. Veronese N. Tsiptsios D. Tsamakis K. Stewart R. Mueller C. -Weight loss in Alzheimer-s disease vascular dementia and dementia with Lewy bodies]Dementia with Lewy bodiesbusiness.industryAlzheimer's disease dementia hospitalization Lewy bodies mortality weight lossHazard ratioAlzheimer's diseasemedicine.diseasemortalityConfidence intervalPsychiatry and Mental healthCohortGeriatrics and Gerontologymedicine.symptomweight lossbusinessLewy bodiesdementiahospitalization
researchProduct

Legal liability in bisphosphonate-related osteonecrosis of the jaw

2014

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an adverse reaction that may occur in patients administered with bisphosphonates (BP). This condition can cause high morbidity and hinder quality of life. Its treatment is complex and often unsatisfactory, and prevention strategies may have limited effectiveness, if any. Thus, managing patients treated with BP may result in exposure of the practitioner to legal liability or malpractice claims: legal actions pursuant to BRONJ are reported to be underway on three continents. Nonetheless, the attribution of liability, if any, is a complex process requiring, on the basis of current knowledge, a robust and pragmatic approach to the facts…

medicine.medical_specialtybisphosphonate jawLegal liabilitybusiness.industrymedicine.medical_treatmentLiabilitySettore MED/50 - Scienze Tecniche Mediche ApplicateLiability LegalBisphosphonatemedicine.diseaseSurgeryQuality of life (healthcare)Settore MED/28 - Malattie OdontostomatologicheMalpracticemedicineHumansBisphosphonate-Associated Osteonecrosis of the JawCausationMedical prescriptionOsteonecrosis of the jawIntensive care medicinebusinessGeneral Dentistry
researchProduct

Demographic and behavioural profiles of patients with common oral mucosal lesions by a homogeneity analysis

2012

Oral Diseases (2012) 18, 396–401 Objective:  The aim of this study is to assess the main oral mucosal lesions (OMLs) within a hospital base and to provide an anamnestic, diagnostic model based on homogeneity analysis of some variables. Methods:  The demographic and behavioural data (i.e. gender, age, smoking status, alcohol consumption and therapeutic drug usage) of 1753 patients with at least one OML were considered. Multiple correspondence analysis (MCA) and multivariate tests of the simultaneous marginal homogeneity hypothesis (SMH) were used to analyse the evidence of any differences between the demographic and behavioural profiles relating to OMLs diagnoses. Statistical significance of…

medicine.medical_specialtybusiness.industryDentistryBurning mouth syndromeRecurrent aphthous stomatitismedicine.diseaseDrug userOtorhinolaryngologyMultiple correspondence analysisStatistical significanceInternal medicinemedicinemedicine.symptombusinessOsteonecrosis of the jawGeneral DentistryOral medicineLeukoplakiaOral Diseases
researchProduct

Review of: "Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial"

2020

medicine.medical_specialtybusiness.industryGeneral EngineeringBone healingPlacebomedicine.diseaseSurgerylaw.inventionRandomized controlled triallawTeriparatidemedicinebusinessOsteonecrosis of the jawmedicine.drugQeios
researchProduct